Pandion Therapeutics Company

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Technology: Regenerative Medicine
Industry: Biotechnology, Health Care, Therapeutics, Wellness
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2017-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 11
Total Funding: $138M
Estimated Revenue: $1M to $10M
Last Funding Type: Series B

Visit Website
Register and Claim Ownership